Literature DB >> 20373984

Identification of two novel mutations in the RET proto-oncogene in the same family.

Kalliopi Pazaitou-Panayiotou1, Christoforos Giatzakis, George Koutsodontis, Athanassios Vratimos, Alexandra Chrisoulidou, Themistoklis Konstantinidis, Smaragda Kamakari.   

Abstract

BACKGROUND: Activating germline mutations of the RET gene cause multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma (FMTC), conditions that are inherited in an autosomal dominant manner. In addition, somatic RET mutations have been identified in a variable proportion (about 30-70%) of sporadic (nonfamilial) MTC cases.
METHODS: We describe a Greek family with two novel likely pathogenic sequence variants of the RET gene. The first is a C to T transition at position 2458 (c.2458C>T) that causes an arginine to cysteine substitution (p.R820C) in exon 14 in the intracellular region of the kinase. This sequence variant was identified in an apparently healthy woman who had a recently deceased sister with confirmed aggressive MTC (age of onset 37 years). To assess the pathogenicity of this novel missense sequence variant, screening was performed on all available relatives: her two sons, the mother, and a second sister, including an MTC tumor sample from the deceased sister of the proband. At the time of the investigation, no clinical symptoms suggestive of multiple endocrine neoplasia type 2 or MTC were present in any of the individuals screened.
RESULTS: The c.2458C>T transition was found in one son, the living sister, and the mother. Interestingly, it was not present in the tumor sample from the deceased sister. Instead, an in-frame deletion of 54 nt in exon 10 resulting in a protein missing 18 amino acids from I590 to G608 (c.1766_1819del 54) was found. Both genetic alterations were present in heterozygous state.
CONCLUSIONS: These data suggest that the novel in-frame deletion was the disease-causing mutation in the deceased sister. The effect of the 2458C>T mutation on the activity of the kinase is under investigation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20373984     DOI: 10.1089/thy.2009.0262

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  3 in total

Review 1.  Hereditary medullary thyroid carcinoma: the management dilemma.

Authors:  Ping Zhou; Jian Liu; Shao-Wen Cheng; Bing Wang; Rong Yang; Ling Peng
Journal:  Fam Cancer       Date:  2012-06       Impact factor: 2.375

Review 2.  Precision oncology for RET-related tumors.

Authors:  Antonella Verrienti; Giorgio Grani; Marialuisa Sponziello; Valeria Pecce; Giuseppe Damante; Cosimo Durante; Diego Russo; Sebastiano Filetti
Journal:  Front Oncol       Date:  2022-08-24       Impact factor: 5.738

3.  A Case of medullary thyroid carcinoma with de novo V804M RET germline mutation.

Authors:  Young Sik Choi; Hye Jung Kwon; Bu Kyung Kim; Su Kyoung Kwon; Yo Han Park; Jeong Hoon Kim; Sang Bong Jung; Chang Hoon Lee; Seong Keun Lee; Shinya Uchino
Journal:  J Korean Med Sci       Date:  2013-01-08       Impact factor: 2.153

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.